Glycocalyx as Possible Limiting Factor in COVID-19

Front Immunol. 2021 Feb 22:12:607306. doi: 10.3389/fimmu.2021.607306. eCollection 2021.

Authors

Patricia P Wadowski¹, Bernd Jilma², Christoph W Kopp¹, Sebastian Ertl^{1

2}, Thomas Gremmel^{1

3}, Renate Koppensteiner¹

Affiliations

¹ Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
² Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
³ Department of Internal Medicine I, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.

No abstract available

Keywords: COVID-19; SARS-CoV-2; complement; glycocalyx; heparan sulfate.

Publication types

Review

MeSH terms

COVID-19 / metabolism
COVID-19 / pathology
COVID-19 / virology*
Endothelium / pathology
Endothelium / virology
Glycocalyx / metabolism
Glycocalyx / pathology
Glycocalyx / virology*
Heparitin Sulfate / metabolism
Humans
SARS-CoV-2 / pathogenicity*

Substances

Heparitin Sulfate